Maker of medical devices: catheters, blood-management systems and infusion/hospital products.
Maker of medical devices: catheters, blood-management systems and infusion/hospital products.
Sells single-use devices that hospitals and blood centers reorder, so revenue is repeat purchasing rather than one-off equipment. Overseas markets account for most of sales. It bought the US blood-technology business now called Terumo BCT in 2011, which gave it a large presence in blood processing.
In one line: Japan's Becton Dickinson/Boston Scientific.
Moat: narrow (IP / patents, regulatory licence, installed base). Long-standing regulatory approvals and hospital-purchasing relationships across catheter/blood-device lines.
Headquarters: Tokyo, Japan · Founded: 1921 · Employees: 31,185
Size Terumo (4543.T) is a Japan Health Care company (Medical Specialties) with a market value of $24.0B, the 71st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,534 on 18 Nov 2026.
Performance Over six months the shares gained 31.8%, against +26.0% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 15.0% over the last twelve months (peer median +6.7%); the operating margin is 17.0% (peer median 19.3%).
Valuation It trades at 27.8× forward earnings against a peer median of 28.0× (10th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.8 points above its cost of capital (7.2% WACC).
Credit Terumo has 1 bond outstanding ($500M), rated A- by the agencies and trading like AA- at a weighted spread of 54 bp.
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥1.22T | ¥1.13T | ¥1.04T | ¥922B | ¥820B |
| Revenue growth | — | +9% | +12% | +12% | — |
| Gross profit | ¥647B | ¥566B | ¥533B | ¥454B | ¥394B |
| EBITDA | ¥315B | ¥280B | ¥264B | ¥211B | ¥188B |
| Net income | ¥114B | ¥136B | ¥117B | ¥106B | ¥89.3B |
| Free cash flow | ¥199B | ¥146B | ¥142B | ¥85.6B | ¥64.8B |
| Capital expenditure | ¥100B | ¥102B | ¥82.4B | ¥78.8B | ¥72.2B |
| Total debt | ¥317B | ¥427B | ¥214B | ¥269B | ¥267B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Terumo 4543.T | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% |
| Becton Dickinson BDX | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% |
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 17.9× | 16.5% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4543.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.3% | +6.1% | 9th highest of 21 |
| 6-month return | +31.8% | +26.0% | 9th highest of 21 |
| Distance from 52-week high | -5.8% | -8.4% | 8th highest of 21 |
| Revenue growth (TTM) | +15.0% | +6.7% | 5th highest of 21 |
| Operating margin | 17.0% | 19.3% | 9th lowest of 21 |
| Forward P/E | 27.8× | 28.0× | 10th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 8.8% | 16.2% | 7th least demanding of 18 |
| Growth delivered (Del g) | +13.0% | +8.3% | 4th highest of 18 |
| Hurdle (Req g minus delivered) | -4.2 pp | +4.2 pp | 4th least demanding of 18 |
| ROIC minus cost of capital | +1.8 pp | +3.2 pp | 9th lowest of 21 |
| EV / EBITDA | 12.2× | 20.8× | 3rd cheapest of 17 |
| Net debt / EBITDA | 0.0× | 1.2× | 4th least indebted of 17 |
| Bond spread | 54 bp | 90 bp | tightest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Terumo 4543.T | Japan | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% | +13.0% |
| Sartorius Stedim Biotech DIM.PA | France | $24.2B | +32% | +4% | 19% | 45.7× | 33.4% | +9.2% |
| Steris STE | United States | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% | +13.8% |
| West Pharmaceutical Services WST | United States | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% | +7.4% |
| Straumann STMN.SW | Switzerland | $20.4B | +20% | +2% | 21% | 32.9× | 16.2% | +12.8% |
| Sartorius SRT.DE | Germany | $19.9B | +26% | +4% | 18% | 43.0× | 25.6% | +8.7% |
| Sonova SOON.SW | Switzerland | $19.8B | +40% | -6% | 23% | 25.3× | 6.0% | +6.7% |
| Guardant Health GH | United States | $19.6B | +26% | +42% | -39% | n/a | n/a | n/a |
| Zimmer Biomet ZBH | United States | $19.6B | +21% | +7% | 16% | 11.7× | 7.4% | +3.2% |
| Dexcom DXCM | United States | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% | +19.3% |
| Illumina ILMN | United States | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% | +6.0% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | China | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% | +9.7% |
| Revvity RVTY | United States | $17.0B | +61% | +5% | 16% | 26.2× | 26.4% | -5.5% |
| ResMed RMD | United States | $34.1B | +16% | +9% | 34% | 19.7× | 5.7% | +12.1% |
| Mettler Toledo MTD | United States | $34.6B | +60% | +7% | 29% | 33.7× | 20.1% | +5.5% |
| Coloplast A/S COLO-B.CO | Denmark | $16.6B | +24% | +4% | 25% | 20.0× | -2.1% | +8.3% |
| Alcon ALC.SW | Switzerland | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% | +6.1% |
| GE HealthCare GEHC | United States | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% | +3.7% |
| Shanghai United Imaging Healthcare 688271.SS | China | $14.4B | +4% | +27% | 9% | 45.7× | n/a | n/a |
| Glaukos GKOS | United States | $13.8B | +62% | +47% | -9% | 161.5× | n/a | n/a |
| Lenskart Solutions LENSKART.NS | India | $13.6B | +49% | +35% | 10% | 137.7× | 53.2% | +33.5% |
Terumo has 1 bond outstanding with $500M face value. The agencies rate it A-; its bonds trade like AA-. Weighted yield 5.36%, a spread of 54 bp over government bonds.